BPLP Inhibitors
BPLP Inhibitors encompass a diverse array of chemical compounds that indirectly diminish the functional activity of BPLP through interference with specific signaling pathways and molecular interactions. For instance, the mTOR pathway, pivotal in regulating cell growth, is targeted by Rapamycin, resulting in the attenuation of downstream processes that could involve BPLP. Similarly, the PI3K/AKT signaling axis, which is integral to cell survival and metabolism, is compromised by inhibitors such as LY 294002 and Wortmannin, leading to a potential decrease in BPLP activity if it is regulated by these pathways. The MAPK/ERK and p38 MAPK pathways, associated with cell proliferation and stress responses, respectively, are also targeted; PD 98059 and SB 203580 act as specific inhibitors, with the likelihood of diminishing BPLP activity should it be linked to these pathways. Furthermore, the JNK pathway, which regulates apoptosis, is impeded by SP600125, which could indirectly result in reduced BPLP function.
Further expanding the arsenal of BPLP inhibitors, the Hedgehog signaling pathway, a determinant in cell differentiation, is disrupted by Cyclopamine, potentially impacting BPLP's activity. G protein-coupled receptor signaling, affected by NF449, also plays a role in the modulation of BPLP by inhibiting the Gs alpha subunit, which could be a regulatory factor for BPLP. Additionally, the proteasome pathway, which facilitates protein degradation, is targeted by MG132, leading to an indirect inhibition of BPLP through stress-induced pathways. The transcription factor NF-κB, known to regulate gene expression in response to inflammation and cellular stress, is inhibited by Triptolide, thus potentially diminishing BPLP if its function is coupled with NF-κB-mediated signaling. Lastly, ZM-447439 targets Aurora kinases, which are critical for mitosis, and by inhibiting these kinases, BPLP activity could be indirectly reduced if it is associated with cell cycle regulation. Collectively, these inhibitors orchestrate a multifaceted diminution of BPLP by acting on distinct but interrelated signaling networks and biological processes.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively inhibits mTOR (mammalian target of rapamycin), which is a crucial regulator of cell growth and proliferation. By inhibiting mTOR, rapamycin can diminish the activity of downstream proteins that rely on mTOR signaling for their activation or stability, potentially including BPLP if it is implicated in mTOR-dependent pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). PI3K pathway is involved in numerous cellular functions, including cell growth and survival. Inhibiting PI3K can lead to a reduction in AKT signaling, which could diminish BPLP activity if BPLP's function or stability is regulated by AKT-mediated signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 selectively inhibits MEK, which is part of the MAPK/ERK pathway, a key pathway in cell proliferation and differentiation. By inhibiting MEK, PD98059 can lead to a decrease in ERK activation. If BPLP activity relies on ERK signaling for any of its functional aspects, this inhibition could indirectly diminish BPLP's functional activity. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB 203580 is a specific inhibitor of p38 MAPK, a member of the MAPK family involved in cellular stress responses. Inhibition of p38 MAPK can disrupt downstream signaling which could indirectly diminish the activity of BPLP if it is involved in pathways or cellular processes that are regulated by p38 MAPK. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an inhibitor of PI3K, similar to LY294002, and leads to downstream inhibition of AKT signaling. By diminishing AKT signaling, wortmannin could indirectly decrease BPLP activity if BPLP is involved in or regulated by PI3K/AKT pathways. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine is an inhibitor of the Hedgehog signaling pathway by binding to the Smoothened receptor. If BPLP is implicated in the Hedgehog pathway, either directly or indirectly, this could lead to decreased functional activity of BPLP by inhibiting the pathway's signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in controlling numerous cellular processes, such as apoptosis. Inhibiting JNK signaling could diminish BPLP activity if BPLP is regulated by or involved in JNK-related cellular responses. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
NF449 is a potent and selective antagonist of the Gs alpha subunit of G protein-coupled receptors. If BPLP activity is modulated through G protein-coupled receptor signaling, particularly via the Gs pathway, NF449 could lead to a decrease in BPLP activity by obstructing this signaling route. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can lead to the accumulation of polyubiquitinated proteins and potentially inhibit degradation pathways. If BPLP is targeted for degradation by the proteasome, the inhibition by MG132 could paradoxically increase BPLP levels initially but eventually could lead to a functional inhibition due to unfolded protein response activation. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide is a diterpene triepoxide that has been found to inhibit the transcriptional activity of NF-κB. If BPLP activity or expression is NF-κB-dependent, the use of triptolide could result in diminished BPLP activity by inhibiting this transcription factor. | ||||||